2023 World Conference on Lung Cancer (Posters)-EP13.03. Clinical Effectiveness of First-Line Immunotherapy in Small Cell Lung Cancer

EP13.03. Clinical Effectiveness of First-Line Immunotherapy in Small Cell Lung Cancer - PDF(Abstract)

Pdf Summary

A study conducted at Montefiore Medical Center aimed to determine if Hispanic and Black patients with small cell lung cancer (SCLC) experience similar clinical benefits from first-line immunotherapy compared to other racial and ethnic groups. The study included a retrospective review of records from patients diagnosed with extensive SCLC between 2016 and 2021 who received first-line immunotherapy. The demographic and clinical data of Hispanic, non-Hispanic Black, and non-Hispanic White patients were compared, and Cox proportional hazard regression was used to determine the impact of race/ethnicity on overall survival (OS) and progression-free survival (PFS).<br /><br />Among the 51 identified SCLC patients who received first-line immunotherapy, 25.5% identified as non-Hispanic Black and 45.1% as Hispanic. Patients from these racial and ethnic backgrounds were more likely to live in areas with lower median income and have Medicaid or Dual Medicare-Medicaid insurance. However, the study found no statistically significant differences in OS and PFS between Hispanic, non-Hispanic Black, and non-Hispanic White patients.<br /><br />Overall, the study observed comparable clinical effectiveness in terms of OS and PFS among the cohort of metastatic SCLC patients who received first-line immunotherapy, including patients from diverse racial and ethnic backgrounds. The study highlights the importance of evaluating the impact of immunotherapy on minority groups, as there is limited information available on this subject.

Asset Subtitle

Matthew Lee

Meta Tag

Speaker Matthew Lee

Topic SCLC & Neuroendocrine Tumors: First Line Therapy

Keywords

Montefiore Medical Center

Hispanic patients

Black patients

small cell lung cancer

SCLC

clinical benefits

first-line immunotherapy

racial and ethnic groups

overall survival

progression-free survival